Skip to main content
. 2023 Apr 19;45(4):830–838. doi: 10.1007/s11096-023-01569-x

Fig. 3.

Fig. 3

Risk of adverse events leading to treatment discontinuation. Legend: 1, Placebo; 2, ruxolitinib; 3, tofacitinib; 4, delgocitinib; 5, triamcinolone acetonide cream (TAC); 6, tacrolimus